United States Federal Circuit
Bristoll-Myers Squibb Co. v. Teva Pharms. USA, Inc., 2013-1306
In a patent infringement case concerning a drug for the treatment of hepatitis B, the district court's finding of a claim 8 invalid for obviousness, is affirmed where Teva proved by clear and convincing evidence that claim 8 would have been obvious.
Appellate Information
- Decided 06/12/2014
- Published 06/12/2014
Judges
- Chen
Court
- United States Federal Circuit